Tag: Aerie Pharmaceuticals (AERI)
Aerie’s successful new confirmatory study for Rhopressa® was a necessity
Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa ® (netarsudil ophthalmic solution ) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This...
Read More
August 15, 2018
0
Exelixis and Aerie Have Good News
Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare ( MHLW ) for approval to manufacture and to sell Exelixis’ ( EXEL ) product Cabometyx® (cabozantinib)...
Read More
April 25, 2019
0
Confirmed as Therapeutic Molecules, Alnylam’s RNAI Made the Most Important News of the Week and the Year
The Week in Review #5 ALNYLAM (ALNY) a nd Sanofi Genzyme , the specialty care global business unit of Sanofi announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for hereditary ATTR amyloidosis with polyneuropathy, met...
Read More
September 25, 2017
0
Prohost Letter #414
Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s updates and comments...
Read More
October 25, 2017
0
The FDA Approved Aerie Pharmaceuticals’ Glaucoma Eye Drops Rhopressa. What’s Next?
Two months ahead of the PDUFA date scheduled for February 28, 2018, the Food and Drug Administration (FDA) approved Aerie Pharmaceuticals’ (AERI) ophthalmic solution) 0.02% Rhopressa ® (netarsudil for the lowering of elevated intraocular pressure (IOP) in open-angle glaucoma....
Read More
December 22, 2017
0
The Year in Review Part 1
Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regarding the degree of their positive impact...
Read More
December 31, 2017
0
Exelixis and Aerie Have Good News
Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare ( MHLW ) for approval to manufacture and to sell Exelixis’ ( EXEL ) product Cabometyx® (cabozantinib)...
Read More
April 25, 2019
0
Aerie’s successful new confirmatory study for Rhopressa® was a necessity
Aerie Pharmaceuticals (AERI) announced results from a double-masked, randomized, placebo-controlled study designed to evaluate the effect of its glaucoma product Rhopressa ® (netarsudil ophthalmic solution ) 0.02% on aqueous humor dynamics in patients with open-angle glaucoma or ocular hypertension. This...
Read More
August 15, 2018
0
Exelixis and Aerie Have Good News
Exelixis & Aerie Have Good News Exelixis' Good News about Cabometyx Takeda Pharmaceuticals applied to the Japanese Ministry of Health, Labor and Welfare ( MHLW ) for approval to manufacture and to sell Exelixis’ ( EXEL ) product Cabometyx® (cabozantinib)...
Read More
April 25, 2019
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)